New rinse aims to stop deadly heart device infections
NCT ID NCT07158502
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether TauroPace, an antimicrobial solution, can prevent infections in people getting implantable heart devices like pacemakers. Infections after these surgeries are rare but serious, sometimes fatal. The trial will compare TauroPace to standard saline rinsing in 1000 adults.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- TauroPace (taurolidine solution)
- What this could lead to
- If it works, this could provide a simple, non-antibiotic way to prevent serious infections after heart device surgery.
- What could go wrong
- This is a single study with 1000 people. TauroPace may not reduce infections more than standard care, and rare allergic reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2025
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients undergoing implantation or generator replacement of cardiovascular implantable electronic devices (CIEDs). Participants will be consecutively enrolled during routine clinical activity over the study period.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Clinical indication for CIED implantation or generator replacement * Signed informed consent to participate in the study Exclusion Criteria: * Known allergy to taurolidine or any of the excipients * Severe immunodeficiency status (e.g., patients undergoing chemotherapy, with AIDS, or immunosuppressed following organ transplantation) * Life expectancy \< 12 months due to severe comorbidities (e.g., metastatic cancer, end-stage organ failure) * Pregnant or breastfeeding women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cied-related infections are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.